Back to News
Market Impact: 0.4
Iovance Biotherapeutics Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Iovance Biotherapeutics reported record third-quarter revenue of approximately $122 million, up 80% year over year. Sales of its melanoma treatment AMTAGVI exceeded $100 million for the first time in a quarter.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
IOVA0.75
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook